Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Celastrus Paniculatus | Vinpocetine | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 500-1000 mg/day of seed extract (standardized to >8% polyphenols) or 10-15 seeds daily (traditional Ayurvedic dosing, escalated from 1 seed/day) | 5-20 mg 2-3 times daily (15-60 mg/day total) |
| Timing | Morning, with or without food. Traditional practice involves gradual dose escalation starting from 1 seed daily, increasing by 1 seed per day up to 10-15. | With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours). |
| Cycle Duration | Traditionally used in 30-60 day courses. No established cycling protocol from clinical data. | Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
Seed oil contains sesquiterpenes, alkaloids (celastrine, paniculatin), and polyunsaturated fatty acids that demonstrate dose-dependent cholinergic activity by inhibiting acetylcholinesterase (AChE) and increasing acetylcholine levels in hippocampal and cortical regions. Provides neuroprotection against oxidative stress through elevation of glutathione (GSH), catalase (CAT), and superoxide dismutase (SOD). Seed extracts attenuate hydrogen peroxide- and glutamate-induced excitotoxic injury in neuronal cells, and exhibit anti-inflammatory and anxiolytic properties.
500-1000 mg/day of seed extract (standardized to >8% polyphenols) or 10-15 seeds daily (traditional Ayurvedic dosing, escalated from 1 seed/day)
Morning, with or without food. Traditional practice involves gradual dose escalation starting from 1 seed daily, increasing by 1 seed per day up to 10-15.
Traditionally used in 30-60 day courses. No established cycling protocol from clinical data.
Semi-synthetic derivative of vincamine (from Vinca minor/periwinkle) that selectively inhibits phosphodiesterase type 1 (PDE1) in cerebral vasculature, increasing cAMP and cGMP levels to promote vasodilation and restore regional cerebral blood flow without significant systemic blood pressure effects. Reduces intracellular calcium in smooth muscle cells and neurons. Inhibits voltage-gated sodium channels, providing neuroprotection against excitotoxicity. Potent anti-inflammatory agent via direct inhibition of IKK, attenuating NF-kB signaling. Downstream CREB and SRF phosphorylation promotes expression of plasticity-related genes.
5-20 mg 2-3 times daily (15-60 mg/day total)
With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours).
Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →